|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two deleterious somatic mutations in TP53 and BRCA2 genes were shared between retroperitoneal HGSC and STIC.
|
30744657 |
2019 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriers of BRCA1 and BRCA2 mutations are at increased risk of high grade serous carcinoma and are therefore offered risk-reducing salpingo-oophorectomy (RRSO) by 40-45 years.
|
30894273 |
2019 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The goal of the study is to report the frequency of subsequent BC and high-grade serous carcinoma (HGSC) following RRSO in BRCA1 and BRCA2 mutation carriers and in patients with personal history of BC with or without BRCA mutation.
|
30055521 |
2018 |
|
High grade serous carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High expression levels of HER2 and PD-L1 were more commonly observed in CCC patients (12.6% vs 2.7%, 21.1% vs 11.6%, P = 0.006, 0.064, respectively), while loss of BRCA1 and BRCA2 expression were more frequently occurred in HGSC patients (72.6% vs 54.3%, 89.4% vs 79.8%, P = 0.007, 0.054, respectively).
|
28187748 |
2017 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, 79% of tumors were classified as high-grade serous carcinoma (n=138), and the most common mutations in high-grade serous carcinomas were TP53 (94%), BRCA1 (25%), BRCA2 (11%), and ATM (7%).
|
27150160 |
2016 |
|
High grade serous carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Substantial progress has been made in identifying genes that are associated with a high risk of ovarian cancer (such as BRCA1 and BRCA2), as well as a precursor lesion of HGSC called serous tubal intraepithelial carcinoma, which holds promise for identifying individuals at high risk of developing the disease and for developing prevention strategies.
|
27558151 |
2016 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
If true, an increased incidence of uterine papillary serous carcinomas would be expected in BRCA1 and BRCA2 mutation carriers, who are at high-risk of developing pelvic high-grade serous carcinoma.
|
23080033 |
2013 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We explored the molecular changes in HGSC arising in association with specific BRCA1/BRCA2 somatic or germline mutations and in those with BRCA1 DNA promoter methylation.
|
23633455 |
2013 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In all, 103 cases were high-grade serous carcinoma and of these 31 (30%) had germline or somatic BRCA1 or BRCA2 mutations (20% BRCA1 and 10% BRCA2) (group 1), 21 (20%) had methylation of BRCA1 (group 2), and in 51 (50%) there was no BRCA loss (group 3).
|
22282309 |
2012 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Women who have inherited germline mutations of BRCA1/BRCA2 are at increased risk of developing high-grade serous carcinoma, and many of these cancers arise in the distal fimbriated end of the fallopian tube.
|
22967960 |
2012 |
|
High grade serous carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DNA ploidy and gene expression profile were used in order to compare gross genomic alteration and gene expression pattern between cases with BRCA1 loss through mutation, BRCA1 epigenetic loss, and no BRCA1 loss in cases of high-grade serous carcinoma with known BRCA1 and BRCA 2 status.
|
20843305 |
2010 |